UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (2567) 2567
life sciences & biomedicine (2544) 2544
humans (2115) 2115
braf (2103) 2103
mutation (1666) 1666
proto-oncogene proteins b-raf - genetics (1546) 1546
oncology (1428) 1428
female (1141) 1141
melanoma (1118) 1118
male (1112) 1112
middle aged (929) 929
adult (782) 782
aged (769) 769
gene mutations (672) 672
pathology (664) 664
genetic aspects (640) 640
cancer (596) 596
tumors (530) 530
neoplasms (518) 518
metastasis (498) 498
braf mutation (476) 476
colorectal cancer (470) 470
prognosis (451) 451
melanoma - genetics (440) 440
immunohistochemistry (402) 402
analysis (397) 397
aged, 80 and over (376) 376
melanoma - drug therapy (357) 357
research (356) 356
vemurafenib (352) 352
thyroid neoplasms - genetics (351) 351
digestive system diseases (347) 347
kinases (347) 347
thyroid cancer (346) 346
melanoma - pathology (341) 341
proto-oncogene proteins b-raf - metabolism (337) 337
medicine & public health (336) 336
care and treatment (332) 332
dna mutational analysis (332) 332
proto-oncogene proteins b-raf - antagonists & inhibitors (328) 328
kras (321) 321
colorectal neoplasms - genetics (309) 309
endocrine system diseases (308) 308
cell biology (302) 302
braf v600e (289) 289
young adult (282) 282
animals (280) 280
cell line, tumor (275) 275
papillary thyroid carcinoma (270) 270
thyroid neoplasms - pathology (263) 263
biomarkers, tumor - genetics (259) 259
patients (253) 253
mutation - genetics (246) 246
adolescent (242) 242
antineoplastic agents - therapeutic use (238) 238
retrospective studies (237) 237
surgery (230) 230
targeted therapy (223) 223
chemotherapy (222) 222
health aspects (221) 221
skin neoplasms - genetics (220) 220
colorectal neoplasms - pathology (213) 213
braf inhibitor (210) 210
proteins (205) 205
skin neoplasms - pathology (205) 205
ras proteins - genetics (202) 202
treatment outcome (201) 201
development and progression (200) 200
dermatology (199) 199
immunotherapy (198) 198
dabrafenib (191) 191
metastases (188) 188
microsatellite instability (179) 179
neurosciences & neurology (178) 178
protein kinase inhibitors - therapeutic use (177) 177
gene expression (172) 172
nras (171) 171
child (169) 169
skin neoplasms - drug therapy (169) 169
medical prognosis (167) 167
protein kinase inhibitors - pharmacology (167) 167
proto-oncogene proteins - genetics (162) 162
clinical neurology (160) 160
neoplasm staging (160) 160
neoplasms. tumors. oncology. including cancer and carcinogens (160) 160
thyroid (160) 160
deoxyribonucleic acid--dna (157) 157
thyroid cancer, papillary (157) 157
diagnosis (156) 156
polymerase chain reaction (155) 155
signal transduction (154) 154
proto-oncogene proteins p21 (152) 152
antineoplastic agents - pharmacology (151) 151
skin cancer (150) 150
cancer therapies (148) 148
genes (148) 148
biochemistry & molecular biology (147) 147
braf v600e mutation (146) 146
pharmacology & pharmacy (146) 146
ras (143) 143
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3607) 3607
Chinese (70) 70
German (30) 30
French (24) 24
Japanese (12) 12
Spanish (10) 10
Russian (9) 9
Korean (8) 8
Polish (6) 6
Portuguese (5) 5
Czech (2) 2
Norwegian (2) 2
Turkish (2) 2
Hungarian (1) 1
Persian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of oncology, ISSN 0923-7534, 07/2017, Volume 28, Issue 7, pp. 1631 - 1639
...) and overall survival (OS) with combination dabrafenib and trametinib versus dabrafenib monotherapy in BRAF V600E/K-mutant metastatic melanoma... 
trametinib | melanoma | durable outcomes | BRAF | metastatic | dabrafenib | Life Sciences & Biomedicine | Oncology | Science & Technology | Index Medicus
Journal Article
Acta neuropathologica, ISSN 1432-0533, 10/2011, Volume 123, Issue 2, pp. 223 - 233
Journal Article
The lancet oncology, ISSN 1470-2045, 07/2016, Volume 17, Issue 7, pp. 984 - 993
Journal Article
Nature (London), ISSN 1476-4687, 01/2012, Volume 483, Issue 7387, pp. 100 - 103
Inhibition of the BRAF(V600E) oncoprotein by the small-molecule drug PLX4032 (vemurafenib) is highly effective in the treatment of melanoma... 
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Erlotinib Hydrochloride | Receptor, Epidermal Growth Factor - agonists | Apoptosis - drug effects | Colorectal Neoplasms - genetics | Humans | Antineoplastic Agents - therapeutic use | Antibodies, Monoclonal, Humanized | Receptor, Epidermal Growth Factor - metabolism | RNA Interference | Colorectal Neoplasms - drug therapy | HEK293 Cells | Female | Indoles - pharmacology | Antineoplastic Agents - pharmacology | Cetuximab | Proto-Oncogene Proteins B-raf - metabolism | Proto-Oncogene Proteins B-raf - chemistry | Melanoma - metabolism | Colorectal Neoplasms - enzymology | Antibodies, Monoclonal - pharmacology | Enzyme Activation - drug effects | Sulfonamides - pharmacology | Drug Synergism | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Xenograft Model Antitumor Assays | Animals | Sulfonamides - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Quinazolines - therapeutic use | Melanoma - drug therapy | Cell Line, Tumor | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Feedback, Physiological - drug effects | Indoles - therapeutic use | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Colorectal Neoplasms - pathology | Quinazolines - pharmacology | Drug Resistance, Neoplasm - drug effects | Proteins | Library collections | Studies | Phosphorylation | Kinases | Tumors | Index Medicus
Journal Article
Journal Article
Journal Article
Annals of oncology, ISSN 0923-7534, 07/2017, Volume 28, Issue 7, pp. 1631 - 1639
...) and overall survival (OS) with combination dabrafenib and trametinib versus dabrafenib monotherapy in BRAF V600E/K-mutant metastatic melanoma... 
Life Sciences & Biomedicine | Oncology | Science & Technology | Skin Neoplasms - drug therapy | Oximes - pharmacokinetics | Oximes - adverse effects | Humans | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Imidazoles - pharmacokinetics | Protein Kinase Inhibitors - adverse effects | Pyridones - administration & dosage | Time Factors | Melanoma - genetics | Skin Neoplasms - mortality | Protein Kinase Inhibitors - pharmacokinetics | Skin Neoplasms - pathology | Double-Blind Method | Drug Administration Schedule | Pyridones - pharmacokinetics | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Risk Factors | Kaplan-Meier Estimate | Treatment Outcome | Disease Progression | Melanoma - secondary | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Pyrimidinones - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Biomarkers, Tumor - genetics | Pyrimidinones - administration & dosage | Mutation | Pyridones - adverse effects | Melanoma - mortality | trametinib | durable outcomes | metastatic | melanoma | BRAF | Original | dabrafenib
Journal Article
The Journal of pathology, ISSN 0022-3417, 04/2014, Volume 232, Issue 5, pp. 492 - 498
...‐targeted drugs in vitro. In the quest for mutations downstream of EGFR that could explain this apparent discrepancy, Sanger sequencing revealed an oncogenic BRAF V600E mutation in the cell... 
targeted therapy | odontogenic tumour | BRAF | oncogenic mutation | EGFR | ameloblastoma | Pathology | Oncology | Life Sciences & Biomedicine | Science & Technology | Ameloblastoma - drug therapy | Receptor, Epidermal Growth Factor - genetics | Jaw Neoplasms - drug therapy | Humans | Middle Aged | Drug Resistance, Neoplasm | Male | Ameloblastoma - enzymology | Molecular Targeted Therapy | Jaw Neoplasms - pathology | Patient Selection | Dose-Response Relationship, Drug | Young Adult | Receptor, Epidermal Growth Factor - metabolism | Aged, 80 and over | Biomarkers, Tumor - metabolism | Adult | Female | Ameloblastoma - pathology | Antineoplastic Agents - pharmacology | Jaw Neoplasms - enzymology | Proto-Oncogene Proteins B-raf - metabolism | Cell Survival - drug effects | Genetic Predisposition to Disease | Gene Frequency | Ameloblastoma - genetics | Phenotype | Signal Transduction - drug effects | Proto-Oncogene Proteins B-raf - genetics | Adolescent | Cell Line, Tumor | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Biomarkers, Tumor - genetics | Protein Kinase Inhibitors - pharmacology | Mutation | Receptor, ErbB-4 | Jaw Neoplasms - genetics | Immunohistochemistry | Genetic aspects | Gene mutations | Analysis | Pathogenesis | Index Medicus | Original Papers
Journal Article